Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk (NVO ... North Carolina. The Denmark-based advanced unit is mainly intended for the production of drugs used to treat rare diseases, like hemophilia, that are otherwise neglected.

Novo Nordisk (Copenhagen: NOVOB), the market leader in diabetes treatments, is a good example of this type of stock. Diabetes is the world’s fastest-growing major disease. There were 108 million ...

The headquarters is located in Copenhagen (Denmark) with offices in San Francisco, Boston and Singapore. The total assets of Novo Holdings amount to 108 billion euros. Novo Nordisk is a corporate fund ...

Headquarters of pharmaceutical company Novo Nordisk in Copenhagen, Denmark, on Sept. 26, 2023. (Tom Little/File photo / Reuters Photos) In the latest trial that spanned 68 weeks, 61.9% of patients ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned it was considering legal action against companies it believes to be ...

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes ... will be returned to Novo Nordisk's facilities in Denmark – on the ...

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...